(Q42648851)

English

A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension (English)

1 reference

Europe PubMed Central

4 November 2017

arterial hypertension

0 references

open-angle glaucoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

T Aung

1

1 reference

Europe PubMed Central

4 November 2017

P T Chew

2

1 reference

Europe PubMed Central

4 November 2017

C C Yip

3

1 reference

Europe PubMed Central

4 November 2017

Y H Chan

4

1 reference

Europe PubMed Central

4 November 2017

J L See

5

1 reference

Europe PubMed Central

4 November 2017

C G Khng

6

1 reference

Europe PubMed Central

4 November 2017

S T Hoh

7

1 reference

Europe PubMed Central

4 November 2017

L H Ng

8

1 reference

Europe PubMed Central

4 November 2017

H M Lee

9

1 reference

Europe PubMed Central

4 November 2017

language of work or name

0 references

publication date

1 May 2001

1 reference

Europe PubMed Central

4 November 2017

American Journal of Ophthalmology

1 reference

Europe PubMed Central

4 November 2017

131

1 reference

Europe PubMed Central

4 November 2017

5

1 reference

Europe PubMed Central

4 November 2017

636-642

1 reference

Europe PubMed Central

4 November 2017

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Anterior uveitis associated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900943-0

7 January 2021

Identifiers

10.1016/S0002-9394(00)00943-0

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42648851&oldid=1964443171"